Lumos Diagnostics secures initial development services contract with Aptatek

Lumos Diagnostics Holdings Limited (ASX: LDX) announced that it secured a development contract with New Jersey-based Aptatek Biosciences, Inc. to develop a product to assist with screening for phenylketonuria (PKU).

The initial phase of this partnership is expected to generate at least US$0.5 million in revenue for development of an assay and reader. Further, the potential revenue from additional development and ongoing instrument manufacturing activities would depend on successful completion of the initial phase by the end of CY2022. Aptatek is targeting to start additional studies and activities using the test developed by Lumos in Q1 CY2023, with US commercial launch scheduled later in CY2023.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au